Prostate cancer is the most common cancer among the geriatric male population. It is a major health concern, especially in developed countries with a greater proportion of elderly men being affected by it. According to European Association of Urology, 2016, the incidence is highest in Northern and Western Europe (> 200 per 100,000 men with age group > 70 years of age), while rates in Eastern and Southern Europe have showed a continuous increase. Thus, the introduction of innovative drugs for patients with prostate cancer is required to meet the unmet needs with satisfactory results. Currently, metastatic castration-resistant prostate cancer (CRPC) is usually treated with chemotherapy (docetaxel, and cabazitaxel) or secondary hormonal therapeutic agents such as abiraterone or Triptorelin. Immunotherapy with Sipuleucel-T is prescribed in treating asymptomatic or minimally metastatic CRPC without visceral metastasis.
Market Dynamics
The market is gaining significant traction due to continuous investment by research organizations and universities for the development of therapeutic products for the treatment of such tumors. Novel therapies are expected to be predominately approved in castration-resistant patients, and to compete with better-established treatments, such as Zytiga, Xtandi and generic docetaxel, or to act as adjuvants to established therapies. For instance, there is a strong pipeline of products such as Metformin (Mansoura University), Avelumab (Duke University Medical Center), LY2452473 (Dana-Farber Cancer Institute), which are in their phase 2 studies and are projected to enter the market in the near future. However, high cost and side effects associated with drugs can restraint the market growth.
Key features of the study:
- This report provides in-depth analysis of the prostate cancer therapeutics market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2025, considering 2016 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global prostate cancer therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
- Key companies covered as a part of this study include Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion and marketing tactics.
- The global prostate cancer therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for prostate cancer therapeutics market, research and consulting firms, new entrants and financial analysts
- Various strategy matrices used in analyzing the prostate cancer therapeutics market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
- Global Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Global Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Prostate Cancer Therapeutics Market, By Geography:
- North America
- U.S.
- U.S. Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- U.S. Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Canada
- Canada Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Canada Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- U.K.
- U.K. Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- U.K. Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Germany
- Germany Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Germany Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Italy
- Italy Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Italy Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- France
- France Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- France Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Spain
- Spain Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Spain Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Russia
- Russia Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Russia Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Europe
- Rest of Europe Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Rest of Europe Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia-Pacific
- China
- China Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- India
- India Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- India Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Japan
- Japan Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Japan Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- ASEAN
- ASEAN Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- ASEAN Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Australia
- Australia Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Australia Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- South Korea
- South Korea Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- South Korea Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Asia Pacific
- Rest of Asia Pacific Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Rest of Asia Pacific Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- Brazil
- Brazil Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Brazil Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Mexico
- Mexico Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Mexico Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Latin America
- Rest of Latin America Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Rest of Latin America Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- GCC
- GCC Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- GCC Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Israel
- Israel Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Israel Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Middle East
- Rest of Middle East Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Rest of Middle East Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- North Africa
- North Africa Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- North Africa Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Central Africa
- Central Africa Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Central Africa Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- South Africa
- South Africa Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- South Africa Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Future Plans
- Astellas Pharma Inc.
- AstraZeneca Plc
- Sanofi
- Bayer AG
- Pfizer, Inc.
- Dendreon Corporation (Sanpower Group Co. Ltd.)
- Ipsen Group
- Tolmar Inc.
- Endo International plc
- AbbVie, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
